Histone deacetylases as regulators of inflammation and immunity
- PMID: 21570914
- DOI: 10.1016/j.it.2011.04.001
Histone deacetylases as regulators of inflammation and immunity
Abstract
Histone deacetylases (HDACs) remove an acetyl group from lysine residues of target proteins to regulate cellular processes. Small-molecule inhibitors of HDACs cause cellular growth arrest, differentiation and/or apoptosis, and some are used clinically as anticancer drugs. In animal models, HDAC inhibitors are therapeutic for several inflammatory diseases, but exacerbate atherosclerosis and compromise host defence. Loss of HDAC function has also been linked to chronic lung diseases in humans. These contrasting effects might reflect distinct roles for individual HDACs in immune responses. Here, we review the current understanding of innate and adaptive immune pathways that are regulated by classical HDAC enzymes. The objective is to provide a rationale for targeting (or not targeting) individual HDAC enzymes with inhibitors for future immune-related applications.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.Cardiovasc Res. 2011 Jun 1;90(3):413-20. doi: 10.1093/cvr/cvr003. Epub 2011 Jan 13. Cardiovasc Res. 2011. PMID: 21233251 Review.
-
HDAC inhibitors for the treatment of cancer.Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Curr Opin Investig Drugs. 2003. PMID: 14763127 Review.
-
Epigenetic regulation of airway inflammation.Curr Opin Immunol. 2007 Dec;19(6):694-700. doi: 10.1016/j.coi.2007.07.016. Epub 2007 Aug 27. Curr Opin Immunol. 2007. PMID: 17720468 Review.
-
Function of histone deacetylase inhibitors in inflammation.Crit Rev Immunol. 2011;31(3):233-63. doi: 10.1615/critrevimmunol.v31.i3.40. Crit Rev Immunol. 2011. PMID: 21740352 Review.
-
Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.J Cell Physiol. 2006 Dec;209(3):611-6. doi: 10.1002/jcp.20781. J Cell Physiol. 2006. PMID: 17001696 Review.
Cited by
-
PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: with the involvement of the HDAC3/microRNA-195-5p/SGK1.Clin Epigenetics. 2022 Oct 20;14(1):131. doi: 10.1186/s13148-022-01336-1. Clin Epigenetics. 2022. PMID: 36266728 Free PMC article.
-
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Immunol Cell Biol. 2012 Jan;90(1):55-65. doi: 10.1038/icb.2011.96. Epub 2011 Nov 22. Immunol Cell Biol. 2012. PMID: 22105512 Free PMC article. Review.
-
Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1139-H1149. doi: 10.1152/ajpheart.00156.2016. Epub 2016 Sep 16. Am J Physiol Heart Circ Physiol. 2016. PMID: 27638876 Free PMC article.
-
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.Am J Hematol. 2012 Apr;87(4):354-60. doi: 10.1002/ajh.23112. Epub 2012 Feb 24. Am J Hematol. 2012. PMID: 22367792 Free PMC article.
-
Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype.Mol Biol Cell. 2015 Sep 15;26(18):3178-89. doi: 10.1091/mbc.E15-04-0209. Epub 2015 Jul 29. Mol Biol Cell. 2015. PMID: 26224317 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources